Suppr超能文献

内皮素介导的血管生长需要通过表皮生长因子受体的反式激活作用,经由p42/p44丝裂原活化蛋白激酶和p70 S6激酶级联反应来实现。

Endothelin-mediated vascular growth requires p42/p44 mitogen-activated protein kinase and p70 S6 kinase cascades via transactivation of epidermal growth factor receptor.

作者信息

Iwasaki H, Eguchi S, Ueno H, Marumo F, Hirata Y

机构信息

Second Department of Internal Medicine, Tokyo Medical and Dental University, Japan.

出版信息

Endocrinology. 1999 Oct;140(10):4659-68. doi: 10.1210/endo.140.10.7023.

Abstract

Endothelin-1 (ET-1), a potent endothelium-derived vasoconstrictor peptide, exerts a growth-promoting effect on vascular smooth muscle cells, implicating its pathogenic role in vascular remodeling. To gain insight into the cellular and molecular mechanism whereby ET-1 induces vascular growth, we studied whether transactivation of receptor tyrosine kinases, such as epidermal growth factor receptor (EGFR) and platelet-derived growth factor receptor, are required for activation of p42/p44 mitogen-activated protein (MAP) kinase and p70 S6 kinase (p70S6K), and subsequent growth-promotion by ET-1 in cultured rat vascular smooth muscle cells. Immunoblotting with antiphosphotyrosine antibody revealed that ET-1 rapidly (within 2 min) and transiently induced tyrosine phosphorylation of several proteins, among which 180-kDa protein was shown to be EGFR. ET-1 rapidly increased association of EGFR and Shc with glutathione-S-transferase-Grb2 fusion protein. The ET-1-induced activation of MAP kinase was reduced by an EGFR kinase inhibitor (AG1478) but not by a platelet-derived growth factor receptor kinase inhibitor (AG1296). AG1478 dose-dependently decreased ET-1-stimulated MAP kinase activity as well as [3H]leucine and [3H]thymidine uptake. The ET-1-induced tyrosine phosphorylation of EGFR, as well as MAP kinase activation, was inhibited by an ETA receptor antagonist and intracellular Ca2+ antagonists but not by an ETB receptor antagonist, pertussis toxin, or protein kinase C inhibitors. In addition, dominant negative mutant of H-Ras and a MAP kinase kinase (MEK-1) inhibitor (PD98059) completely blocked ET-1-induced MAP kinase activation as well as [3H]leucine and [3H]thymidine uptake. Both AG1478 and PD98059 inhibited ET-1-induced phosphorylation and activation of p70S6K. Furthermore, rapamycin, a selective inhibitor of mammalian target of rapamycin, completely blocked ET-1-stimulated [3H]leucine and [3H]thymidine uptake. These results suggest that ETA receptor-mediated vascular growth by ET-1 requires both MAP kinase and p70S6K cascades mediated partly via Ca2+-dependent EGFR transactivation.

摘要

内皮素 -1(ET -1)是一种强效的内皮源性血管收缩肽,对血管平滑肌细胞具有促生长作用,提示其在血管重塑中具有致病作用。为深入了解ET -1诱导血管生长的细胞和分子机制,我们研究了受体酪氨酸激酶(如表皮生长因子受体(EGFR)和血小板衍生生长因子受体)的反式激活是否是ET -1激活p42/p44丝裂原活化蛋白(MAP)激酶和p70 S6激酶(p70S6K)以及随后在培养的大鼠血管平滑肌细胞中促进生长所必需的。用抗磷酸酪氨酸抗体进行免疫印迹分析显示,ET -1迅速(在2分钟内)且短暂地诱导了几种蛋白质的酪氨酸磷酸化,其中180 kDa的蛋白质被证明是EGFR。ET -1迅速增加了EGFR和Shc与谷胱甘肽 -S -转移酶 -Grb2融合蛋白的结合。EGFR激酶抑制剂(AG1478)可降低ET -1诱导的MAP激酶激活,但血小板衍生生长因子受体激酶抑制剂(AG1296)则无此作用。AG1478剂量依赖性地降低ET -1刺激的MAP激酶活性以及[3H]亮氨酸和[3H]胸苷摄取。ETA受体拮抗剂和细胞内Ca2 +拮抗剂可抑制ET -1诱导的EGFR酪氨酸磷酸化以及MAP激酶激活,但ETB受体拮抗剂、百日咳毒素或蛋白激酶C抑制剂则无此作用。此外,H -Ras的显性负突变体和MAP激酶激酶(MEK -1)抑制剂(PD98059)完全阻断了ET -1诱导的MAP激酶激活以及[3H]亮氨酸和[3H]胸苷摄取。AG1478和PD98059均抑制ET -1诱导的p70S6K磷酸化和激活。此外,雷帕霉素(一种雷帕霉素哺乳动物靶标的选择性抑制剂)完全阻断了ET -1刺激的[3H]亮氨酸和[3H]胸苷摄取。这些结果表明,ET -1通过ETA受体介导的血管生长需要部分通过Ca2 +依赖性EGFR反式激活介导的MAP激酶和p70S6K级联反应。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验